Nitrase Therapeutics Presented Data on the Importance of Synuclein Nitrase on the Synaptic Activity of Differentiated Dopaminergic Neurons at the Society for Neuroscience (SFN) Conference
BRISBANE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, a new class of enzymes discovered in-house that are involved in a broad variety of diseases, today announced the company presented the poster titled “Synuclein Nitrase, a Novel Enzyme that Catalyzes Nitration of Synuclein, Modulates Dopaminergic Neuron Activity” (abstract #110.04 / B29) at the Society for Neuroscience 2022 (SFN) conference held from November 12-16, 2022 in San Diego, CA.
- In preclinical studies, Nitrase examined the effect of knocking out Synuclein Nitrase on the survival, growth and electrical activity of differentiated dopaminergic neurons (iDAs) derived from human iPSC lines from both non-PD and familial PD (fPD) patients.
- Knocking out Synuclein Nitrase also reduced synuclein accumulation in the insoluble fraction of preformed fibril (PFF) treated iDAs.
- These studies establish that reducing Synuclein Nitrase levels can reduce electrophysiological deficits and insolubility of synuclein in PD iDA neurons.
- These data demonstrate that targeting Synuclein Nitrase could serve as a novel disease-modifying therapeutic for patients with Parkinsons disease.